NeuroSigma Announces Positive Pilot Study Results for Monarch eTNS in ADHD
Summary
NeuroSigma announced positive results from a pilot study evaluating its Monarch external trigeminal nerve stimulation system for attention-deficit hyperactivity disorder. The study showed improvements in attention and reduction in hyperactivity symptoms in children and adolescents after treatment with the non-invasive neurostimulation device. The Monarch system delivers mild electrical stimulation to the trigeminal nerve through a wearable device.
Why it matters
ADHD affects millions of children and adults worldwide, with many patients not responding adequately to or experiencing side effects from stimulant medications. Non-invasive neurostimulation could offer a drug-free alternative for ADHD treatment. Positive pilot data support further development of trigeminal nerve stimulation for this large and underserved patient population.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial